Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, IRLAB Therapeutics AB's Enterprise Value is kr198.33 Mil.
IRLAB Therapeutics AB's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 was kr-92.03 Mil. Therefore, IRLAB Therapeutics AB's EV-to-OCF for today is -2.16.
The historical rank and industry rank for IRLAB Therapeutics AB's EV-to-OCF or its related term are showing as below:
OSTO:IRLAB A'
s EV-to-OCF Range Over the Past 10 Years
Min: -52.62 Med: -10.39 Max: 15.83
Current: -2.16
During the past 13 years, the highest EV-to-OCF of IRLAB Therapeutics AB was 15.83. The lowest was -52.62. And the median was -10.39.
OSTO:IRLAB A's EV-to-OCF is ranked worse than 57.57% of 1407
companies
in the Biotechnology industry
Industry Median: -3.45
vs OSTO:IRLAB A: -2.16
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
IRLAB Therapeutics AB (OSTO:IRLAB A) EV-to-OCF Explanation
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
IRLAB Therapeutics AB's PE Ratio (TTM) for today is calculated as:
IRLAB Therapeutics AB's share price for today is kr1.516.
IRLAB Therapeutics AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-1.018.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:IRLAB A vs VRTX, REGN, RVMD: EV-to-OCF Comparison
For the Biotechnology subindustry, IRLAB Therapeutics AB's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
IRLAB Therapeutics AB EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, IRLAB Therapeutics AB's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where IRLAB Therapeutics AB's EV-to-OCF falls into.
IRLAB Therapeutics AB's current Enterprise Value is kr198.33 Mil.
IRLAB Therapeutics AB's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-92.03 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IRLAB Therapeutics AB (OSTO:IRLAB A) has a EV-to-OCF of -2.16 as of Aug. 09, 2026. According to the industry distribution chart, IRLAB Therapeutics AB ranks #810 out of 1407 companies in the Biotechnology industry, placing it in the top 57.6%.
Is IRLAB Therapeutics AB's EV-to-OCF too high?
IRLAB Therapeutics AB's current EV-to-OCF is -2.16. Based on the distribution chart, IRLAB Therapeutics AB ranks #810 out of 1407 companies in the Biotechnology industry, which is below the industry midpoint. Overall, IRLAB Therapeutics AB has a GF Score™ of 36/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does IRLAB Therapeutics AB's EV-to-OCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, IRLAB Therapeutics AB ranks #810 out of 1407 companies for EV-to-OCF. This places IRLAB Therapeutics AB in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. IRLAB Therapeutics AB's current EV-to-OCF is -2.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IRLAB Therapeutics AB stock overvalued right now?
Based on GuruFocus' analysis, IRLAB Therapeutics AB (OSTO:IRLAB A) is currently considered Possible Value Trap. The stock's GF Value™ is kr11.65, compared to a current price of kr1.52 — trading 87% below its estimated fair value. The current EV-to-OCF is -2.16. IRLAB Therapeutics AB's overall GF Score™ is 36/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For IRLAB Therapeutics AB (OSTO:IRLAB A), the current EV-to-OCF is -2.16 as of Aug. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is IRLAB Therapeutics AB (OSTO:IRLAB A) Overvalued in 2026?
Based on GuruFocus' analysis, IRLAB Therapeutics AB stock appears to be undervalued.
The current stock price of kr1.52 is trading 87% below its estimated GF Value™ of kr11.65.
GuruFocus considers IRLAB Therapeutics AB to be Possible Value Trap.
Key valuation signals for OSTO:IRLAB A:
EV-to-OCF: -2.16
GF Value™: kr11.65 vs. price of kr1.52 (87% below fair value)
No single metric tells the full story. See the OSTO:IRLAB A stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
IRLAB Therapeutics AB is a drug discovery and development company providing novel treatments for disorders of the brain. The company focuses on treatments and quality of life for patients with neurological and psychiatric illnesses. It is engaged in programs targeting core dysfunctions in Parkinson's disease and dementias. In addition, it is also involved in the clinical development of novel compounds that aims to offer improved clinical benefit for patients with Parkinson's disease. The company's current clinical candidates, mesdopetam (IRL790) and pirepemat (IRL752), both of which have successfully gone through Phase I safety and Phase IIa efficacy proof-of-concept studies, are now in Phase IIb trials.
36GF Score
Get the complete analysis for OSTO:IRLAB A
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:IRLAB A has been successfully added to your 
